The Effect of Didrogesteron and Horethisterone on Lipid Peroxidation in Female Patients with Simple Endometrial Hyperplasia

The aim of the investigation is to study the effect of progestins: didrogesteron and norethisterone on lipid peroxidation in blood plasma of female patients with simple endometrial hyperplasia.

Materials and Methods. There were examined 38 women with simple endometrial hyperplasia. There were two groups: the first one (n=20) consisted of patients taking didrogesteron (Dufaston) in a dose of 20 mg a day, the second group (n=18) was taking norethisterone (Norkolut), 10 mg a day. Both medications were taken daily, within 90 days.
The investigations of the activity lipid peroxidation process and the intensity of free radical lipid peroxidation were carried out before and 3 months after the therapy.

Results. Didrogesteron reduces the level of diene, triene and conjugates and Schiff bases, while norethisterone, on the contrary, leads to sufficient growth of these indexes. In addition, both medications increase the activity of antioxidant system. The data obtained suggest the control of lipid peroxidation indexes for the whole course of treatment.

1. Gasparyan N.D., Kareva E.N., Gorenkova O.S., Ovchinnikova E.Yu. Rossiyskiy vestnik akushera-ginekologa 2004; 4: 27–30.
2. Reed S.D., Newton K.M., Garcia R.L. et al. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. Obstet Gynecol 2010; 116(2 Pt 1): 365–373.
3. Brun J.L., Descat E., Boubli B., Dallay D. Endometrial hyperplasia: A review. J Gynecol Obstet Biol Reprod (Paris) 2006; 35(6): 542–550.
4. Dubossarskaya Z.M., Dubossarskaya Yu.A. Zhinochyj likar 2009; 5: 22–27.
5. Feeley K.M., Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001; 54(6): 435–440.
6. Smetnik V.P. ZGT i serdechno-sosudistaya sistema. Zashchitnoe vliyanie estrogenov na serdechno-sosudistuyu sistemu. Consilium medicum 2002; ekstravypusk: 3–6.
7. Zhang Y. Cardiovascular diseases in American women. Nutr Metab Cardiovasc Dis 2010; 20(6): 386–393.
8. Morimoto K., Morikawa M., Kimura H. et al. Mental stress induces sustained elevation of blood pressure and lipid peroxidation in postmenopausal women. Life Sci 2008; 82(1–2): 99–107.
9. Rosselli M., Imthurn B., Keller P.J. et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995; 25(4 Pt. 2): 848–853.
10. Guetta V., Quyyumi A.A., Prasad A. et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997; 96(9): 2795–2801.
11. Kallikazaros I., Tsioufis C., Zambaras P. et al. Estrogen-induced improvement in coronary flow responses during atrial pacing in relation to endothelin-1 levels in postmenopausal women without coronary disease. Vasc Health Risk Manag 2008; 4(3): 705–714.
12. Mazire C., Auclair M., Ronveaux M.F. et al. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991; 89(2–3): 175–182.
13. Perera M., Sattar N., Petrie J.R. et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2001; 86(3): 1140–1143.
14. Roof R.L., Hall E.D. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 2000; 17(5): 367–388.
15. Borisenkov M.F., Efimtseva E.A., Chelpanova T.I. et al. Ros Fiziol Z Im I.M. Sechenova 2006; 92(9): 1136–1146.
16. Sayeed I., Stein D.G. Progesterone as a neuroprotective factor in traumatic and ischemic brain injury. Prog Brain Res 2009; 175: 219–237.
17. Kalashnikova M.F., Sych Yu.P., Katkhuriya Yu.B., Mel’nichenko G.A. Ross Med Z 2000; 8(11): 461–464.
18. Africander D., Verhoog N., Hapgood J.P. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76(7): 636–652.
19. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000; 65(10–11): 651–658.
20. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009; 65(1): 3–11.
21. Gungor F., Kalelioglu I., Turfanda A. Vascular effects of estrogen and progestins and risk of coronary artery disease: importance of timing of estrogen treatment. Angiology 2009; 60(3): 308–317.
22. Seeger H., Mueck A.O. Effects of dydrogesterone on the vascular system. Gynecol Endocrinol 2007; 23(1): 2–8.

Obukhov L.R., Kuzin V.B., Barsuk А.L., Okrut I.Е. The Effect of Didrogesteron and Horethisterone on Lipid Peroxidation in Female Patients with Simple Endometrial Hyperplasia. Sovremennye tehnologii v medicine 2011; (4): 181